Trials / Completed
CompletedNCT00161876
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,973 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 16 Years – 66 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers aged 16 to 65 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Timeline
- Start date
- 2002-05-01
- Completion
- 2002-08-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
8 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT00161876. Inclusion in this directory is not an endorsement.